Quantinno Capital Management LP Increases Stake in Medline $MDLN

Quantinno Capital Management LP grew its position in Medline (NASDAQ:MDLN) by 91.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 45,739 shares of the company’s stock after acquiring an additional 21,837 shares during the period. Quantinno Capital Management LP’s holdings in Medline were worth $2,035,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in MDLN. SummitTX Capital L.P. purchased a new stake in Medline in the 1st quarter valued at approximately $4,780,000. Lazard Asset Management LLC boosted its stake in shares of Medline by 100.2% in the first quarter. Lazard Asset Management LLC now owns 26,448 shares of the company’s stock valued at $1,177,000 after buying an additional 13,239 shares in the last quarter. Weiss Asset Management LP grew its holdings in Medline by 1.3% during the first quarter. Weiss Asset Management LP now owns 213,178 shares of the company’s stock worth $9,486,000 after acquiring an additional 2,787 shares during the period. OMERS ADMINISTRATION Corp acquired a new position in Medline during the first quarter worth $423,000. Finally, Bradley Foster & Sargent Inc. CT purchased a new position in Medline in the first quarter worth $17,331,000.

Medline Stock Performance

Shares of MDLN stock opened at $35.04 on Wednesday. The stock has a fifty day moving average price of $38.21 and a 200 day moving average price of $41.57. The stock has a market cap of $46.03 billion and a PE ratio of 109.50. Medline has a 1 year low of $32.81 and a 1 year high of $50.88. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.61 and a current ratio of 4.33.

Medline (NASDAQ:MDLN) last posted its earnings results on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.18. The firm had revenue of $7.68 billion for the quarter. Sell-side analysts forecast that Medline will post 1.49 earnings per share for the current fiscal year.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: TD Cowen maintained a Buy rating and set a $45 price target, implying substantial upside from recent levels. The firm cited Medline’s strong cash flow and longer-term growth outlook. TD Cowen Medline rating
• Positive Sentiment: Tigress Financial lowered its price target from $62 to $55 but retained a Buy rating. The revised target still represents significant potential upside, suggesting the analyst views recent weakness as excessive. Benzinga analyst action
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. Because the figures include an apparent “NaN” calculation, the data may be incomplete or unreliable and offers little actionable insight for investors.
• Negative Sentiment: Wells Fargo cut its price target from $45 to $34 and changed its stance to Equal Weight. The new target is slightly below the recent trading level, signaling limited near-term upside in the firm’s view. Wells Fargo Medline price target
• Negative Sentiment: Major shareholder Private Ltd Gic sold approximately 590,284 shares worth $21.0 million, reducing its ownership by 2.36%. While the investor still holds a substantial stake, the sale may add modest pressure or raise concerns about insider sentiment. SEC ownership filing
• Negative Sentiment: Law firm Kaplan Fox announced an investigation into potential securities-law violations involving Medline. The announcement does not establish wrongdoing, but it introduces legal and reputational risk and may weigh on investor confidence. Kaplan Fox Medline investigation

Insider Transactions at Medline

In other Medline news, major shareholder Private Ltd Gic sold 1,976,618 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $35.60, for a total transaction of $70,367,600.80. Following the completion of the transaction, the insider directly owned 25,264,760 shares in the company, valued at approximately $899,425,456. This trade represents a 7.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Douglas P. Golwas sold 100,000 shares of Medline stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the transaction, the insider owned 23,899 shares of the company’s stock, valued at approximately $878,766.23. The trade was a 80.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,938,896 shares of company stock valued at $104,656,454 in the last 90 days. 0.81% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on MDLN. Stifel Nicolaus decreased their target price on shares of Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. TD Cowen cut their price target on shares of Medline from $53.00 to $45.00 and set a “buy” rating for the company in a report on Monday. Barclays cut their price target on shares of Medline from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Monday, June 1st. Robert W. Baird set a $42.00 price objective on shares of Medline in a report on Thursday, August 6th. Finally, William Blair restated an “outperform” rating on shares of Medline in a research report on Thursday, June 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.69.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.